Advanced Therapies Week 2022 | Novel supply chain changes in the advanced therapies space

Julia Tarasenko, MSc, Marken, Durham, NC, describes recent trends in supply chains within the in the cell and gene therapy (CGT) industry. As COVID-19 has greatly disrupted the supply chain, just-in-time manufacturing has become more popular due to a dwindling supply of materials, and products can be produced in a matter of a few days from the procurement of the active pharmaceutical ingredient such as viral vectors. In spite of the pandemic, clinical trials are ongoing for advanced therapies, but the industry must consequently adapt to increased demand. This interview took place at Advanced Therapies Week 2022.